
Recent actions by the Saudi Arabia competition authority confirm that the agency is adopting a more aggressive enforcement approach, particularly involving consumer-facing companies, reported Lexology.com.
The Saudi Arabian General Authority for Competition (“GAC”) recently announced that its board had blocked the Saudi stock exchange-listed National Gas and Industrialization Co. (“GASCO”) from acquiring a majority stake in Saudi Arabia’s Best Gas Carrier Co. (“Best Gas”) from its sole shareholder. GASCO announced the proposed transaction in February 2022. GASCO is a monopoly wholesale distributor of liquid petroleum gas (“LPG”) (principally butane, propane, and mixtures thereof). Best Gas purchases LPG, empty LPG cylinders, and parts from GASCO and sells filled LPG cylinders to end users.
The GAC board’s announcement states that the proposed merger could allow GASCO to use its position as a monopoly supplier to advantage Best Gas by raising fees or reducing the quality of its products and services to Best Gas competitors. According to the GAC board, that conduct would reduce retail competition and harm consumers. GAC rejected the parties’ claim that the merger would result in efficiencies in LPG distribution, finding the efficiencies insufficient in comparison to the potential harm to competition. The GAC statement indicated that it had studied LPG markets in a number of countries and found that most had liberalized competition in the LPG distribution chain. Those countries tended to limit or prevent vertical integration of LPG distribution stages. GAC’s theory of harm and analysis in this transaction are consistent with recent enforcement actions of vertical transactions by other competition agencies, including in the United States and Europe.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas